Adult obesity rate fell from record high-and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and Mounjaro | Fortune
Adult obesity rate fell from record high-and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and Mounjaro | Fortune
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Nov 2025)
Novo Nordisk's Ozempic and Wegovy sales have propelled the company to a valuation exceeding Denmark's GDP and spurred development of additional obesity drugs.
